935 related articles for article (PubMed ID: 17825128)
1. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
4. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the claim of enhanced persistence: the case of osteoporosis and implications for payers.
Kelton CM; Pasquale MK
Med Decis Making; 2009; 29(6):690-706. PubMed ID: 19542361
[TBL] [Abstract][Full Text] [Related]
6. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
7. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM
Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
[TBL] [Abstract][Full Text] [Related]
8. Potential clinical and economic impact of nonadherence with osteoporosis medications.
Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy.
Pham AN; Datta SK; Weber TJ; Walter LC; Colón-Emeric CS
J Am Geriatr Soc; 2011 Sep; 59(9):1642-9. PubMed ID: 21883116
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
[TBL] [Abstract][Full Text] [Related]
11. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
Cotté FE; Fautrel B; De Pouvourville G
Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
[TBL] [Abstract][Full Text] [Related]
13. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
Boonen S
Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
[TBL] [Abstract][Full Text] [Related]
14. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
16. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
17. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
Christensen PM; Brixen K; Gyrd-Hansen D; Kristiansen IS
Basic Clin Pharmacol Toxicol; 2005 May; 96(5):387-96. PubMed ID: 15853932
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]